This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
When a patient needs a new heartvalve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing -- and life-saving -- for many.
When a patient needs a new heartvalve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of UBC Okanagan researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing—and life-saving—for many.
According to Dr. Kendra Grubb , Surgical Director of the Emory Structural Heart & Valve Center , approximately 40%† of patients with aortic stenosis in the United States do not get treatment because their symptoms are often misdiagnosed or ignored2. To explore the TAVR Heart Team Finder, please click here.
Michael Rinaldi , an interventional cardiologist and the medical director of the structural heart program at Atrium Health Sanger Heart & Vascular Institute. "We We have been eagerly anticipating the opportunity to bring this innovative technology to our community. The recent approval of the tricuspid clip device by the U.S.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 The imaging sub-study was a novel assessment of the right side of the heart using cardiac CT and MRI before and after a tricuspid repair procedure. Abbott has announced U.S
I look forward to the continued development of the ZETA device to explore the potential of this breakthrough technology to treat more patients with aortic regurgitation with unmet needs.” For more information: [link] If you enjoy this content, please share it with a colleague
According to Dr. Kendra Grubb , Surgical Director of the Emory Structural Heart & Valve Center , approximately 40%† of patients with aortic stenosis in the United States do not get treatment because their symptoms are often misdiagnosed or ignored2. To explore the TAVR Heart Team Finder, please click here.
Xeltis synthetic restorative pulmonary heartvalve evolves into a fully functioning, natural heartvalve through colonization by the patient’s own tissue. Xeltis’ novel technology has already treated over 100 patients across different clinical trials.
"Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,
Transfemoral access has been the preferred method for transcatheter heartvalve delivery. However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheral artery disease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR). The technology can be embedded into wearable devices, such as everyday in-ear headphones and hearing aids.
milla1cf Wed, 01/31/2024 - 17:10 January 31, 2024 — Royal Philips , a global leader in health technology, announced that its latest TEE transducer, designed to serve more patients with improved overall comfort, has received FDA 510(k) clearance. In many cases, this is a view that is difficult to achieve with traditional 2D TEE.
milla1cf Mon, 05/06/2024 - 10:50 May 6, 2024 — Teleflex Incorporate , a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center.
Image courtesy of Henry Ford Health milla1cf Wed, 02/21/2024 - 19:07 February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart disease patient—and the first ever in Michigan—to receive a new transcatheter heartvalve device for treating severe tricuspid regurgitation.
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management.
Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. 3 Based on internal test report D00997823, Avalus Ultra Full Valve Stiffness Design Verification Report.
tim.hodson Mon, 10/21/2024 - 15:52 Earlier this year, Materialise, a global supplier of 3D printing software and services, acquired FEops , a Belgian company that develops AI-driven simulation technology to improve procedure efficiency and clinical outcomes for structural heart interventions.
This study is designed to evaluate the Corrie Hybrid CR, a technology‐based, multicomponent health equity‐focused intervention as an alternative to traditional in‐center CR among patients recovering from a cardiac event, surgery, or procedure compared with usual care alone.MethodsThe mTECH‐Rehab (Impact of a Mobile Technology Enabled Corrie CR Program) (..)
million Department of Defense grant awarded to the Georgia Institute of Technology (Georgia Tech), Yaxin Wang, PhD (seated left), O.H. The Texas Heart Institute will receive approximately $2.94 He is an expert in prosthetic heartvalves and cardiovascular biomechanics, biomaterials and devices.
His industry roles have included serving as Chief Medical Officer for HLT Medical, a transcatheter heartvalve company, as Chief of Cardiology with Optum/United Health subsidiary SCA Health, and as Medical Director for clinical research organization Medpace. pivotal EMPOWER Trial,” said Dr. Shreenivas. “I
Under the expert guidance of our seasoned instructors and anatomy specialist, this session offered a wealth of practical insights, allowing attendees to delve into the intricacies of heartvalve anatomy.
Material and Methods Patient-specific 3D-printed pulmonary artery geometries of five patients who underwent PPVI using Pulsta transcatheter heartvalve (THV) ® were tested in a modified ViVitro pulse duplicator system®. Various valve sizes were subjected to 10 cycles of testing at different cardiac output levels.
Under the expert guidance of our seasoned instructors and anatomy specialist, this session offered a wealth of practical insights, allowing attendees to delve into the intricacies of heartvalve anatomy.
milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. mmHg TAVR; 11.8 mmHg SAVR; p "The Evolut TAVR System continues to demonstrate positive clinical outcomes compared to SAVR.
After half a century of evidence suggesting the existence of mineralocorticoid receptors (MR) in the vasculature, the advent of technology to specifically knockout the MR from smooth muscle cells (SMCs) in mice has elucidated contributions of SMC-MR to cardiovascular function and disease, independent of the kidney.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content